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Based on its capacity to inhibit de novo pyrimidine 
biosynthesis by blocking dihydroorotate dehydrogenase 
activity, the antitumor agent brequinar sodium (BQR) 
has emerged as a new immunosuppressive agent. Since 
BQR is known to prevent the synthesis of nucleotides 
during cell proliferation, we hypothesized that it would 
be highly effective in controlling strong lymphocyte pro-
liferative responses but might be less effective in con-
trolling comparatively weak responses that do not nec-
essarily involve new nucleotide synthesis. We addressed 
this question by culturing murine spleen cells with dif-
ferent types of stimuli, including Con A, phorbol myris-
tate acetate ± ionomycin, anti-CD3, and anti-Igs. 
Addition ofBQR (0.001 "g/ml to 10 "g/ml) at the start 
of a 72-hr culture period caused dose-dependent inhi-
bition of strong proliferative responses, induced either 
by Con A (5 "g/ml) or PMA + ionomycin. A residual 
degree of proliferation persisted, however, even at the 
highest BQR concentrations. In contrast, no impairment 
of low-concentration Con A (0.5 or 0.1 "g/ml), anti-
CD3, or anti-Igs responses was observed. In order to 
ascertain its role in arresting nucleotide synthesis, we 
attempted to reverse the inhibitory effect of BQR by 
adding exogenous uridine or cytidine to lymphocyte cul-
tures. BQR's inhibitory activity was reversed com-
pletely by adding uridine at 0.1 mM. In contrast, com-
bination of BQR and cytidine (0.1 mM) potentiated 
BQR's activity and abrogated anti-CD3 or anti-Igs-in-
duced lymphocyte proliferation in a dose-dependent 
manner. A synergistic inhibitory action between BQR 
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and cytidine was observed when the BQR concentration 
was higher than 0.1 "g/ml and with cytidine at 0.1 mM. 
Production of interleukin-2 and 1L-4 was only slightly 
affected by BQR, but was significantly suppressed by 
coadministration of BQR and cytidine. Neither BQR (5 
"g/ml) on its own, however, nor combination of BQR 
with cytidine affected production of mRNA for IL-2, IL-
4, or interferon-,¥, as determined by reverse-transcrip-
tion polymerase chain reaction. Our observations sug-
gest that BQR may not only affect dihydroorotate de-
hydrogenase activity, but may also inhibit the enzyme 
cytidine deaminase, which converts cytidine to uridine. 
These anti metabolic effects of BQR complement the 
well-known cytokine synthesis inhibitory actions of 
FK506 or CsA. The combination of BQR and cytidine, 
however, offers a further possibility for inhibition of 
both cytokine production and T and B cell proliferation, 
and may have potential for the control of graft rejection. 
Brequinar sodium (BQR)* is a novel substituted, 4-quinoline 
carboxylic acid derivative, known originally as an anticancer 
drug (1-2). It mediates antitumor activity by inhibiting the 
mitochondrial enzyme dihydroorotate dehydrogenase (DHO-
DH) (3-4) leading to the arrest of cell growth. By inhibiting 
DHO-DH activity, BQR abrogates de novo pyrimidine nucleo-
tide biosynthesis (3-6) (Fig. 1) and consequently synthesis of 
both RNA and DNA during replicative events in tumor cells. 
Like the purine nucleotide biosynthesis inhibitors azathioprine 
(7), mycophenolic acid (the active moiety of RS61443) (8), and 
mizoribine (9), BQR is likely to possess immunosuppressive 
properties (10). Although little has been reported concerning 
the influence of BQR on immune reactivity, there is recent 
evidence that the drug is effective in prolonging both experi-
* BQR, brequinar sodium; CYT, cytidine; PCR, polymerase chain 
reaction; PMA, phorbol12-myristate-13-acetate. 
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FIGURE 1. Flow diagram of the de novo pyrimidine synthetic path-
way and the salvage pathway showing the site of inhibition by BQR. 
The eleven enzymes involved in these pathways are: (1) carbamyl-
phosphate synthetase II; (2) aspartate transcarbamylase; (3) dihydroor-
otase; (4) dihydroorotate dehydrogenase; (5) orotate phosphoribosyl-
transferase; (6) orotidine 5' -monophosphate decarboxylase; (7) nucle-
oside monophosphate kinase; (8) nucleoside diphosphate kinase; (9) 
CTP synthetase; (10) uridine-cytidine kinase; and (11) cytidine deam-
inase. 
mental allograft (J 1, 12) and xenograft survival (13). In addi-
tion, BQR also has beneficial effects in alleviating experimental 
allergic encephalomyelitis (14). 
Prolonged exposure of tumor cells to BQR results in deple-
tion of the nucleotides CTP and UTP (5, 15); its effect on the 
residual pyrimidine pool in normal or activated lymphocytes, 
however, has not been evaluated. It is known that the magni-
tude of lymphocyte activation in vitro, and perhaps also in 
vivo, depends on the types of signal transduction pathway 
involved (16-20). As BQR may be effective in controlling 
nucleotide biosynthesis induced by strong rather than weak 
stimuli (which do not require increases in nucleotide pools) a 
differential inhibitory activity of the drug rather than a gener-
alized antiproliferative action on responses to different types 
of stimulation might be expected. 
According to the role of BQR in inhibiting pyrimidine syn-
thesis, the addition of exogenous uridine or cytidine might be 
expected to bypass the pyrimidine biosynthesis pathway and 
reverse the antiproliferative activity of BQR (salvage pathway 
[Fig. 1)). Thus uridine is converted to UMP and ultimately to 
UTP, from which it is transformed to CTP by CTP synthetase. 
Exogenous cytidine on the other hand, can be deaminated to 
uri dine by cytidine deaminase and converted eventually to UTP 
(21). Alternatively, cytidine may be converted through CMP 
to CTP. Here, however, we present evidence for differential 
effects of exogenous uri dine and cytidine on lymphocyte re-
sponses that is consistent with inhibition of cytidine deaminase 
activity by BQR. The disruption in intracellular nucleotide 
balance induced by cytidine in the presence of BQR potentiates 
the antilymphocytic activity of BQR. In this study, we address 
the possibilities and present evidence that (1) the inhibitory 
activity of BQR is dependent on the strength of stimulation 
and not on the type of signal transduction pathway and that 
(2) cytidine can potentiate BQR's antilymphocytic activity, 
both in terms of cell proliferation and cytokine production. 
MATERIALS AND METHODS 
Animals. Adult, 8-12-week-old, male C57BL/10SnJ mice were pur-
chased from Jackson Laboratory, Bar Harbor, ME. They were main-
tained in the Central Animal Facility of the University of Pittsburgh 
Health Science Center. 
Reagents. Brequinar sodium (DuPont Merck Pharmaceutical Com-
pany, Wilmington, DE) was kindly provided by Dr. L. Makowka, 
Cedars-Sinai Medical Center, Los Angeles, CA. It was dissolved fresh 
daily in filter-sterilized saline at 1 Itg/ml and diluted to working 
concentrations with RPMI-1640 (Gibco, Grand Island, NY), supple-
mented with 2 mM glutamine, 50 U/ml penicillin G sodium, 50 mg/ml 
streptomycin sulfate, 25 mM Hepes, and 10% heat-inactivated fetal 
bovine serum (Gibco, Grand Island, NY). FK506 (Fujisawa Pharma-
ceutical Co., Osaka, Japan) was dissolved initially in absolute ethanol 
and diluted subsequently in RPMI-1640 with 10% FBS. Concanavalin 
A was purchased from Sigma Chemical Co., St. Louis, MO, and was 
dissolved in sterile saline, followed by further dilution in RPMI-1640 
with 10% FBS. Anti-CD3 monoclonal antibody, derived from clone 
KT3, was purchased from Berotec, Oxford, England, UK. Goat anti-
mouse polyvalent immunoglobulin was purchased from Sigma and was 
used as a B cell mitogen. Phorbol 12-myristate-13-acetate (PMA), 
ionomycin, uridine, and cytidine were purchased from Sigma, and were 
dissolved in absolute ethanol (PMA, ionomycin) or saline (uridine, 
cytidine), and finally diluted in RPMI-1640 with 10% FBS. 
Lymphocyte culture. Spleen cells were used for setting up lymphocyte 
cultures. Briefly, spleens were removed aseptically, then disrupted 
mechanically using a pair of sterile forceps. The cells were washed, 
followed by lysis of erythrocytes in Tris-NH.Cl solution, pH 7.2. After 
further washes, the cells were resuspended finally in RPMI-1640 with 
10% FBS. The number of spleen cells was adjusted and 5XI05 cells 
(final volume 0.2 ml) were added to triplicate wells of 96-well round-
bottomed microtiter plates (Corning Glass Works, Corning; NY). Con 
A, PMA, and ionomycin were used at 5 Itg/ml, 1 ng/ml, and 0.5 ItM, 
respectively, and anti-CD3 and anti-Igs antibodies were used at final 
dilutions of 1/100 and 1/50, respectively. For addition of exogenous 
uridine or cytidine, each was used at 0.1 mM (final concentration) 
unless specified. Cells were cultured for 24-120 hr, and 1 ItCi ["H]-
thymidine was added to wells 24 hr before cell harvesting. The degree 
of radioactive thymidine incorporation was measured by a liquid scin-
tillation counter 1205 Betaplate (Pharmacia, Gaithersburg, MD), and 
results expressed as cpm ± 1 SD. 
In cultures set up to determine cell viability, 50 Itl cell suspension 
was collected at 24, 48, and 72 hr, and the number of viable cells 
quantitated by the trypan blue exclusion test. 
Generation of supernatants for cytokine measurement. Fifty million 
spleen cells were cultured with Con A (5 Itg/ml) for 20 hr with/without 
BQR in Falcon tissue-culture tubes (Becton Dickinson, NJ). In some 
cultures, 0.1 mM cytidine was added. After incubation, cultures were 
centrifuged, and supernatants were collected and stored at -80'C until 
analysis. 
Quantitation of IL-2 and IL-4 by "sandwich" ELISA. A murine IL-2 
ELISA kit (Collaborative Research, Bedford, MA) and a murine IL-4 
ELISA kit (Endogen, Boston, MA) were employed for measurement of 
cytokine levels in culture supernatants. Briefly, IL-2 or IL-4 in diluted 
supernatants was captured by specific antibodies precoated on wells of 
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ELISA plates. After incubation and washing, bound IL-2 and IL-4 were 
labeled with peroxidase-conjugated antimurine IL-2 or IL-4 antibodies, 
and the presence of the cytokine-antibody complex was detected after 
addition of substrate o-phenylene-diamine. The reaction was stopped 
by addition of 2 M sulfuric acid, and the absorbance was measured at 
wavelength 490 nM using an ELISA plate reader (MR5OOO, Dynatech, 
Guernsey, Channel Islands). The amount of cytokine was derived from 
standard curves obtained with known IL-2 and IL-4 concentrations 
and performed on the same ELISA plates. 
Detection of cytokine gene expression. Cells were harvested 20 hr 
after Con A stimulation and total RNA extracted by the guanidinium-
isothiocyanate method. A 1 /lg RNA sample was reverse-transcribed 
into cDNA using oligo-dT primer and MML V reverse transcriptase 
(Gibco BRL). This template cDNA was used for 30 cycles of PCR 
amplification, using specific IL-2, IL-4, and IFN-" oligonucleotide 
primers synthesized at the University of Pittsburgh DNA synthesis 
facility. The PCR amplification was carried out using Taq polymerase 
(Perkin-Elmer) and a Model 480 DNA Thermal Cycler (Perkin-Elmer). 
The products of amplification, along with molecular weight markers 
for sizing, were separated on 2% agarose gels stained with ethidium 
bromide and photographed in UV light. Semiquantitative analysis was 
performed by comparing visibility of bands for serial ten-fold dilutions 
of input template DNA. ~-actin primer was used in a separate PCR 
reaction to control for amount of template eDNA. 
RESULTS 
Differential effects of BQR on lymphocyte activation induced 
by strong and weak stimuli. In order to address the question of 
the relationship between upregulation of nucleotide biosyn-
thesis during cell proliferation and the inhibitory action of 
BQR, lymphocytes were cultured with either strong (Con A, 
PMA + ionomycin) or weak (anti-CD3, anti-Igs) stimuli. This 
induced different degrees of lymphocyte activation that re-
quired different extents of de novo nucleotide biosynthesis for 
cell proliferation. Maximal stimulation of 3H-thymidine incor-
poration over 72 hr in response to Con A was achieved using a 
mitogen concentration of 5 /lg/ml. High 3H-thymidine incor-
poration was also achieved with PMA (1 ng/ml) plus ionomycin 
(0.5 /lM). Addition of BQR at the start of cultures resulted in 
concentration-dependent inhibition of DNA synthesis in re-
sponse to either Con A or PMA + ionomycin (Fig. 2a). In 
response to either of these stimulants, the minimally effective 
concentration ofBQR was 0.1 /lg/ml, whereas the ICsos for Con 
A- or PMA + ionomycin-stimulated cells were 0.2 and 0.5 /lg/ 
ml BQR, respectively. Although a sigmoidal dose-response ef-
fect, with approximately 80-90% inhibition at high concentra-
tions of BQR (>5 /lg/ml) was obtained, persistent residual 
augmentation of DNA synthesis corresponding to 30,000-
50,000 cpm (stimulation index 10-20) was observed consist-
ently in these mitogen-stimulated cultures. 
In contrast to the strong inhibitory effect demonstrated by 
BQR on either Con A- or PMA+ionomycin-induced DNA 
synthesis, mitogenic responses of mouse lymphocytes to weak 
stimuli, including anti-CD3 and anti-Igs, showed resistance to 
BQR (Fig. 2b). The extent of thymidine incorporation induced 
by these stimulants was substantially less (by approximately 
one order of magnitude) than that achieved with Con A or 
PMA + ionomycin. BQR (at concentrations that profoundly 
inhibited the response to 5 /lg/ml Con A) failed to inhibit anti-
CD3-induced thymidine incorporation, while no suppression 
but some augmentation of anti-Ig-induced DNA synthesis was 
observed. In contrast, anti-CD3-induced thymidine incorpora-
tion was very sensitive to the anti-T cell agent FK506 (Fig. 
2c). In order to ascertain whether this differential effect on 
Con A, PMA + ionomycin, anti-CD3, and anti-Igs responses 
was due to differences in activation pathways or to the magni-
tude of activation and upregulation of nucleotide synthesis 
required for cell proliferation, different concentrations of Con 
A were added to cultures to provide different degrees of stim-
ulation. As shown in Fig. 2d, the inhibitory effect of BQR on 
Con A responses was dependent both on the concentration of 
the mitogen and the strength of response. The inhibitory effect 
of BQR was attenuated and eventually lost as the Con A 
concentration was reduced from 5.0 to 0.5 /lg/ml. 
Cytotoxicity of BQR. To confirm that the antiproliferative 
effect of BQR was not due to a cytotoxic effect at high drug 
concentration, the number of viable cells was measured follow-
ing 72 hr culture of either unstimulated or Con A (5 /lg/ml)-
stimulated cells with BQR. As shown in Figure 3, BQR at 
inhibitory concentration (5 /lg/ml) did not affect the viable cell 
number in unstimulated cultures (Fig. 3a). It did, however, 
reduce the viable cell number (to approximately that of un stim-
ulated cells) in Con A -stimulated cultures, indicating that BQR 
was not toxic to resting cells but exerted antiproliferative 
activity on Con A-activated lymphocytes. 
Kinetics of the BQR inhibitory effect. To ascertain whether 
the difference in responsiveness to Con A or anti-CD3/lgs in 
the presence of BQR was due to differences in kinetics of the 
respective DNA synthesis, cells were harvested at various times 
after stimulation in the presence of the drug. Inhibitory con-
centrations of 0.5-5.0 /lg/ml BQR at 72 hr were highly effective 
in suppressing Con A-induced thymidine incorporation 
throughout the culture period, while 0.1 /lg/ml BQR had only 
a partial effect (data not shown). In contrast, harvesting of 
cells 24-120 hr after stimulation with anti-CD3 or anti-Igs 
showed no significant inhibitory effect of BQR, even when 
BQR was at 10 /lg/ml (data not shown). 
Influence of exogenous nucleosides on the antiproliferative 
effect of BQR. Since BQR is known to arrest pyrimidine syn-
thesis, its inhibitory effect on cell thymidine incorporation 
might be expected to be reversed by the addition of exogenous 
pyrimidines. When added together with BQR at the initiation 
of Con A-stimulated cultures, however, the nucleosides uridine 
and cytidine had differential effects on lymphocyte thymidine 
incorporation (Fig. 4). While uridine (0.1 mM) prevented com-
pletely the growth inhibitory effect of BQR, the addition of 
cytidine (0.1 mM) resulted in augmentation of the anti-DNA 
synthesis activity of BQR. Indeed, in comparison with BQR 
alone, BQR and cytidine together totally inhibited 3H-thymi-
dine incorporation in the BQR concentration range 0.5-10 /lg/ 
ml. When added alone to cultures, little (cytidine) or no (uri-
dine) inhibitory effect of nucleosides was observed. Neither 
BQR nor cytidine had any direct cytotoxic effect on Con A-
stimulated spleen cell cultures (Fig. 3, b and c). Examination 
of the interaction between BQR and cytidine at various con-
centrations of each agent showed synergistic effects between 
the drugs when the concentration of cytidine was 0.1 mM and 
that of BQR was >0.1 /lg/ml (Fig. 4b). The cpm for untreated 
Con A-stimulated cultures was 154,396±13,147. Addition of 
cytidine at 0.1 mM had very little effect on thymidine incor-
poration (cpm = 141,513±4403). However, the presence of 
cytidine substantially reduced the thymidine incorporation ob-
served with BQR alone (0.5 mg/ml) from cpm 52,630±1490 to 
3151±371, approaching the baseline level of unstimulated cul-
tures. Although a positive interaction between BQR and cyti-
dine was observed consistently, the addition of cytidine did not 
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FIGURE 2. Differential effects of BQR on DNA synthesis induced 
by strong stimuli -optimal concentrations of Con A or PMA + iono-
mycin (a), and weak stimuli-optimal concentrations of anti-CD3 and 
anti·1gs antibodies (b). Anti-CD3-induced DNA synthesis, though re-
sistant to BQR, is highly susceptible to the anti-T cell agent FK506 
(c). The magnitude of BQR's inhibitory effect is dependent on the 
strength of stimulus, as BQR is very effective in inhibiting thymidine 
incorporation induced by 5 ,ug/ml Con A but is less effective at 1 ,ug/ 
ml Con A and ineffective at 0.5 ,ug/ml Con A (d). The cpm of unstim-
ulated cultures in (a) was 1985±372. The cpm for cells cultured with 
lower the minimum inhibitory concentration of BQR. Indeed, 
the occurrence of this positive interaction was dependent on 
the concentration of BQR. 
Due to its augmented anti-DNA synthesis activity against 
Con A-stimulated lymphocytes in the presence of cytidine, a 
combination of BQR with cytidine (0.1 mM) was used to test 
otherwise BQR-resistant anti-CD3 and anti-Igs responses. As 
shown in Figure 5, a and b, the combination of BQR with 
cytidine (0.1 mM) suppressed these responses (Fig. 5, a and b). 
As with suppression of Con A responses, the inhibition of anti-
CD3 and anti-Igs responses was BQR-concentration-depend-
ent. 
The effects of BQR and cytidine on cytokine production. To 
ascertain whether the combination of BQR and cytidine could 
inhibit lymphocyte responses other than DNA synthesis, levels 
of two T cell-derived cytokines (IL-2 and IL-4) were deter-
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Con A or PMA + ionomycin alone in (a) were 220,498±7209 and 
414,394±43,946, respectively. The cpm for unstimulated cultures in (b) 
was 2607±814. The cpm for cells cultured with anti-CD3 or anti-1gs 
alone in (b) were 34,023±2990 and 14,475±1777, respectively. The cpm 
for unstimulated cultures in (c) was 2753±259. The cpm for cultures 
of cells with Con A at 5, 1, and 0.5 ,ug/ml in (d) were 138,097±4352, 
92,903±15,159, and 55,410±11,048, respectively. The cpm for unstim-
ulated cultures in (d) was 3667±1022. Figures shown are representative 
results from 3 separate experiments. 
mined 20 hr after Con A stimulation. Although slight reductions 
in IL-2 and IL-4 levels were observed in cultures with BQR or 
cytidine alone, the combination of BQR and cytidine resulted 
in strong and significant inhibition (P < 0.05) of IL-2 and IL-
4 production (Fig. 6, a and b) when compared with BQR alone 
or cytidine alone. The degree of IL-2 inhibition achieved with 
the drug combination (mean: 63.85%) was significantly higher 
than the added effects of either BQR (mean: 21.95%) or cytidine 
(mean: 16.7%) alone. Similarly, the degree of inhibition of IL-
4 production achieved with drug combination (mean: 86A %) 
was higher than the added effects of either BQR (mean: 13.2%) 
or cytidine (mean: 7.3%) alone, indicating a synergistic inhibi-
tory effect on cytokine production. 
The effects of BQR and cytidine on cytokine gene expression. 
The expression of mRNA for IL-2, IL-4, and IFN-'Y in Con A-
stimulated lymphocytes treated with either BQR or BQR and 
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BQR (b), or Con A-stimulated cells with cytidine (0.1 mM) (c) for a 
period of 72 hr. Viability of cells was determined by trypan blue 
exclusion. At least 200 cells were counted for each sample. 
cytidine was investigated using the reverse transcriptase PCR. 
As shown in Figure 7 (lanes 5,6), BQR alone did not suppress 
message for any of the cytokines investigated. Although BQR 
plus cytidine demonstrated strong inhibition of cytokine pro-
duction (Fig. 6), a strong signal of cytokine mRNA expression 
was still detectable using this drug combination (lanes 7,8) as 
compared with either BQR or cytidine alone. This suggests 
that very early events in lymphocyte activation are not suscep· 
tible to BQR or BQR plus cytidine, and that the inhibition of 
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inhibitory effect, but cytidine at 0.1 mM further potentiated BQR's 
inhibitory action (a). In (b), a synergistic effect between cytidine (0.1 
mM) and BQR (>O.lllg/mi) was observed, while at higher concentra-
tions of cytidine, an additive effect was obtained. The cpm of cultures 
of Can A-stimulated cells, either alone or in the presence of uridine or 
cytidine, were 165,859±5371, 134,123±13,683, and 135,057±16,069, re-
spectively. Figures shown are representative results from 3 separate 
experiments. 
cytokine production we observed depends on the antiprolifer-
ative activity of the drug combination. 
DISCUSSION 
In this study we have confirmed the antiproliferative activity 
of BQR based on its inhibitory action on lymphocyte responses 
stimulated by optimal concentrations of the T cell mitogen, 
Con A. These observations are consistent with the documented 
capacity of BQR to inhibit in vitro tumour cell growth (1, 2) 
and with a recent report of its suppressive effect on allogeneic 
mixed lymphocyte reactions (10). We found that, as with Con 
A responses, BQR inhibited strong mitogenic responses elicited 
by PMA and ionomycin, which together stimulate lymphocytes 
via various intracellular transduction pathways involving pro-
tein kinase C (PKC) activation and the upregulation of intra· 
cellular Ca ++ levels. 
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(a) INHIBITION OF ANTI-CD3 INDUCED 
PROLIFERATION BY BOR+CYTIDINE 
--0-- OORONLY 
--0-- BQR+CYT (0.1 mM) 
.01 .1 10 100 
BaR CONC. (ug/ml) 
(b) INHIBITION OF ANTI-Igs INDUCED 
PROLIFERATION BY BQR+CYTIDINE 
--0-- OORONLY 
--0-- BOR+CYT (0.1 mM) 
.01 .1 10 100 
BOR CONC. (ug/ml) 
FIGURE 5. Inhibition of anti-CD3-induced (a) or anti-Igs-induced 
(b) lymphocyte DNA synthesis by BQR + cytidine, but not by BQR 
alone. The mean cpm of cultures with anti-CD3 alone or anti-Igs alone 
were 19,997±8141 and 24,911±2135, respectively, and with anti-CD3 
+ cytidine or anti-Igs + cytidine they were 16,603±807 and 17,323± 
1413, respectively. Figures shown are representative results from 3 
separate experiments. 
Compared with Con A responses, weaker T cell (anti-CD3)-
specific and B cell (anti-Igs)-specific responses were insensitive 
to BQR, as judged by quantitation of DNA synthesis. This 
differential sensitivity to the drug may simply reflect (in the 
case of weaker mitogenic responses) the availability of suffi-
cient pyrimidine nucleotide reserve during the culture period 
to support nucleic acid synthesis. Stronger stimuli, however, 
evoke proliferative responses that require de novo pyrimidine 
biosynthesis, which is blockaded (via inhibition of dihydrooro-
tate dehydrogenase activity) by BQR. Failure of BQR (10 J.Lg/ 
ml) to inhibit Con A- or PMA + ionomycin-induced responses 
completely (Fig. 2a) may be attributed to use of the pyrimidine 
reserve. We have been unable to locate any previously published 
report demonstrating a similar phenomenon with regard to 
other pyrimidine inhibitors. 
We had anticipated that supplementation of the lymphocyte 
cultures with either uridine or cytidine would prevent the anti-
DNA synthesis activity of BQR. While the inhibitory effect of 
BQR was reversed by uridine as expected, the unexpected 
capacity of cytidine to potentiate the action of BQR leads us 
to speculate that BQR may inhibit the activity of cytidine 
deaminase, the enzyme that mediates the salvage pathway 
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FIGURE 6. Results from 2 separate experiments on IL-2 (a) and IL-
4 (b) production following 20 hr Con A stimulation in the presence of 
BQR, cytidine, or both drugs. In both experiments, slight inhibition of 
IL-2 and IL-4 production was obtained with either BQR (5 "g/ml) 
alone or cytidine (0.1 mM) alone, while strong inhibition was achieved 
by the combination of BQR and cytidine. 
allowing conversion of cytidine to uridine and biosynthesis of 
both CTP and UTP (Fig. 1). This argument is "consistent with 
our observation that addition of exogenous uridine to BQR-
treated cultures must replenish the necessary UTP and CTP-
in the latter instance through the action of CTP synthetase. 
Although both uri dine and cytidine are able to restore cell 
growth in BQR-treated WiDR human adenocarcinoma cells 
(5), cytidine alone is not able to prevent growth inhibition 
induced by BQR in cytidine deaminase-free L1210 mouse leu-
kemia cells (3). If, as we suggest, cytidine deaminase is block-
aded by BQR, the supplement of cytidine can only form CTP 
instead of both nucleotides. Such an imbalance in the UTP / 
CTP ratio would predispose to further adverse effects on cell 
function, including inhibition of aspartate transcarbamyiase, 
an enzyme that regulates an earlier step in the pyrimidine 
biosynthesis pathway (22, 23). This is supported by the obser-
vation that in WiDR cells, the lowest UTP /CTP ratio following 
culture with BQR corresponds to the largest growth inhibition 
(5). Feedback suppression of uridine kinase activity by the 
formation of CTP from exogenous cytidine may offer an alter-
native explanation of cytidine's "enhancing effect." We ob-
served, however, that the augmentory effect of cytidine oc-
curred only with inhibitory BQR concentrations (0.1 J.Lg/ml or 
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FIGURE 7. The expression of cytokine mRNAs in cultured cells was 
measured by semiquantitative P R. Aliquots of amplification products 
from 5 ng RNA (lanes 1,3 ,5 , and 7) and 0.5 ng DNA (Lanes 2,4,6, and 
8) were separated on 2% agarose gel. (Lanes 1 and 2) unstimulated 
mononuclear cells, (lanes 3 and 4) 20-hr Con A-stimulated cells, (lanes 
5 and 6) Con A-stimulated cells in the presence of 5 ILg/ ml BQR (lanes 
7 and 8) Con A-stimulated cells in the presence of 5 ILg/ ml BQR + 0.1 
mM cytidine, (lanes 9 and 10) Con A-stimulated cells with 0.1 mM 
cytidine, (lane ll) molecular weight ladder. Figures shown are repre-
sentative results from 3 separate experiments. 
above). This suggests that certain enzymatic activity must first 
be abrogated before the potentiating effect of cytidine can be 
manifest. It adds credence to t he view that the interaction 
between BQR and cytidine may be due, at least in part, to 
inhibition of cytidine deaminase and consequent accumulation 
of a relative excess of CTP. Complete inhibition of anti-CD3-
or anti-Igs-induced proliferation may also be ascribed to gross 
imbalance in the UTP:CTP ratio as a result of blockade of 
pyrimidine biosynthesis and supplementation with exogenous 
cytidine. The influence of BQR on cytidine deaminase activity 
is now under investigation in our laboratory. 
Earlier events in the lymphocyte cell cycle-e.g., cytokine 
gene expression-were not inhibited by BQR plus cytidine, 
despite strong inhibition of DNA synthesis and cytokine pro-
duction. This finding indicates that, unlike cyclosporine or 
FK506, BQR-plus-cytidine does not effect early lymphocyte 
activation events. Its inhibitory effect on cytokine production 
would, therefore, appear to be based on the anti-DNA synthesis 
property of the drug combination, resulting in availability of 
fewer activated cells for cytokine production (Fig. 3). The 
antimetabolic effect is probably not restricted to cytokine pro-
duction. It is likely, however, that the antimetabolic effect of 
BQR plus cytidine is selective toward metabolically active cells, 
in particular lymphocytes in sites of inflammatory/immune 
reactions. In vivo therapeutic administration of cytidine has 
been performed in cases of congenital pyrimidine deficiency, 
such as orotic aciduria (24). It remains to be determined 
whether a combination of BQR and cytidine may be an effective 
and safe approach to immunosuppressive therapy. 
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